UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029087
Receipt number R000033271
Scientific Title Effect of Bifidobacterium bifidum supplementation on growth and development of term infants at 1 year of age
Date of disclosure of the study information 2017/09/11
Last modified on 2022/08/09 15:19:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of Bifidobacterium bifidum supplementation on growth and development of term infants at 1 year of age

Acronym

Effect of Bifidobacterium on growth and development of term infants

Scientific Title

Effect of Bifidobacterium bifidum supplementation on growth and development of term infants at 1 year of age

Scientific Title:Acronym

Effect of Bifidobacterium on growth and development of term infants

Region

Japan


Condition

Condition

Term infants

Classification by specialty

Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To test the efficacy of Bifidobacterium bifidum OLB6378 on morbidities during the first year
, and growth and development at 1 year of age among term infants

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Phase I,II


Assessment

Primary outcomes

Morbidities during the first year of life

Key secondary outcomes

Growth and development at 1 year of age


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Bifidobacterium bifidum OLB6378 powder (Meiji Co., Ltd., Tokyo, Japan) (0.5g/package) is administered twice a day, and continued until 1 month after birth

Interventions/Control_2

No administration

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

1 months-old <=

Age-upper limit

12 months-old >=

Gender

Male and Female

Key inclusion criteria

Term infants

Key exclusion criteria

Infants with complications

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Satoshi
Middle name
Last name Kusuda

Organization

NPO Neonatal Research Network

Division name

Headquaters

Zip code

110-0015

Address

Higashiueno

TEL

0338350435

Email

skusuda@boshi.twmu.ac.jp


Public contact

Name of contact person

1st name Satoshi
Middle name
Last name Kusuda

Organization

kyorindai university

Division name

Headquaters

Zip code

110-0015

Address

Higashiueno

TEL

0338350435

Homepage URL


Email

kusuda-satoshi@umin.ac.jp


Sponsor or person

Institute

NPO Neonatal Research Network

Institute

Department

Personal name



Funding Source

Organization

NPO Neonatal Research Network

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Shiseikai Daini Hospital
Tokyo Women's Medical University Maternal and Perinatal Center
Meiji Milk Company

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shiseikai 2nd Hospital IRB

Address

5-19-1 Kamisoshigaya, Setagaya, Tokyo

Tel

03-3300-3666

Email

kusuda-satoshi@umin.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

至誠会第二病院


Other administrative information

Date of disclosure of the study information

2017 Year 09 Month 11 Day


Related information

URL releasing protocol

https://britishjournalofgastroenterology.com/

Publication of results

Published


Result

URL related to results and publications

https://britishjournalofgastroenterology.com/

Number of participants that the trial has enrolled

44

Results

In total, 44 infants were enrolled in this study, 21 in the Control (CG) and 23 in the Intervention (IG). Data of 17 infants in the CG and 18 in the IG were analyzed. Groth and developmental quotients at one year of age were not statistically different between the groups. However, infants in the IG had significantly fewer days without defecation.

Results date posted

2022 Year 08 Month 09 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results

2022 Year 04 Month 01 Day

Baseline Characteristics

21 in the Control Group and 23 in the Intervention Group.

Participant flow

Follow-up until 1 year old after the enrollment in the study,

Adverse events

None

Outcome measures

Growth, neurological development, and defecation status

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2017 Year 07 Month 31 Day

Date of IRB

2017 Year 08 Month 01 Day

Anticipated trial start date

2017 Year 08 Month 01 Day

Last follow-up date

2019 Year 12 Month 31 Day

Date of closure to data entry

2020 Year 01 Month 31 Day

Date trial data considered complete

2020 Year 02 Month 01 Day

Date analysis concluded

2020 Year 02 Month 28 Day


Other

Other related information



Management information

Registered date

2017 Year 09 Month 11 Day

Last modified on

2022 Year 08 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033271


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name